EP1399150A4 - Vitamin c compositions - Google Patents

Vitamin c compositions

Info

Publication number
EP1399150A4
EP1399150A4 EP01958837A EP01958837A EP1399150A4 EP 1399150 A4 EP1399150 A4 EP 1399150A4 EP 01958837 A EP01958837 A EP 01958837A EP 01958837 A EP01958837 A EP 01958837A EP 1399150 A4 EP1399150 A4 EP 1399150A4
Authority
EP
European Patent Office
Prior art keywords
vitamin
compositions
hydroxy
compound
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01958837A
Other languages
German (de)
French (fr)
Other versions
EP1399150A1 (en
Inventor
John C Hegenauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ester C Co
Original Assignee
Oxycal Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxycal Laboratories Inc filed Critical Oxycal Laboratories Inc
Priority to EP20140187301 priority Critical patent/EP2859894A1/en
Publication of EP1399150A1 publication Critical patent/EP1399150A1/en
Publication of EP1399150A4 publication Critical patent/EP1399150A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • This invention relates to Vitamin C compositions.
  • this invention relates to Vitamin C compositions suitable for preparing finished products such as cosmetic and dermatologic preparations, food products, e.g., processed foods, beverages, and nutritional supplements, and for preparing medicinal, dental, opthalmic and surgical compositions for both enteral and parenteral introduction.
  • Vitamin C has many known biological functions, e.g., acting as a wound healing accelerant, to prevent or treat periodontal disease, as an enzymatic co-factor,
  • Vitamin C is known to counteract oxygen-containing free radicals, including both the superoxide and hydroxyl radicals. These oxidative free radicals are generated in-
  • vitamin C is known for its ability to ameliorate conditions caused by oxygen free radicals, e.g., sunburn, cataracts, premature aging and a variety of other degenerative conditions.
  • compositions of the invention comprise Vitamin C and a secondary
  • the Vitamin C component which is at least one compound selected from the group consisting of 4- hydroxy-5-methyl-3(2H)-furanone, 3-hydroxy-kojic acid, threose, erythreose, and 5- hydroxymaltol.
  • the Vitamin C component is a mineral ascorbate, i.e., a pharmacologically acceptable salt of ascorbic acid, including salts and complexes of ascorbate anions with
  • alkali elements sodium, potassium, etc.
  • alkaline-earth elements calcium, magnesium, etc.
  • transition elements copper
  • compositions will induce improved dose-dependent, selective apoptosis of diverse human tumor cell-types, even though the concentration of the secondary component in these compositions is very low, i.e., from about .01 to about 1.0% by weight of the total composition.
  • the mineral ascorbates used in practicing the preferred embodiment of the invention are conveniently available as high-purity commercial products. If a single
  • mineral ascorbate is used, it is presently preferred to use calcium ascorbate, although it is contemplated that two or even more mineral ascorbates may be employed,
  • magnesium, sodium, potassium and/or zinc ascorbates and mixtures thereof are effectively employed.
  • the procedures for preparing the compositions of the invention are not critical
  • compositions are merely physically admixed and then tableted with tableting excipients, encapsulated or compression molded to provide convenient dosage forms.
  • the compositions can be prepared as a stable liquid according to the processes disclosed in my issued U.S. Patent 6,197,813.
  • This example illustrates the preparation of a food product, using the
  • compositions of the invention e.g., the compositions of Example 1.
  • Example 1 500 ml of dry granulated sugar is added to 125 ml of water and 125 ml of corn syrup and the mixture is stirred and brouglit to boil at 150°C. Heating is discontinued and cherry flavoring is added to taste and desired color.
  • Product A of Example 1 is added in the quantity required to obtain the desired Vitamin C content, e.g., 30 mg Vitamin C/g of "candy" food product.
  • the composition and the sugar-syrup base are thoroughly mixed for sufficient time to fully disperse the concentrate product. Portions of the resulting hot mixture are transferred to the cavities a candy mold and cooled to form a Vitamin C enriched hard candy product.

Abstract

Vitamin C compositions comprise a Vitamin C compound, preferably a mineral ascorbate, and at least one compound of the group of 4-hydroxy-5-methyl-3(2H)-furanone and 3-hydroxy-kojic acid.

Description

VITAMIN C COMPOSITIONS
This invention relates to Vitamin C compositions.
More particularly, this invention relates to Vitamin C compositions suitable for preparing finished products such as cosmetic and dermatologic preparations, food products, e.g., processed foods, beverages, and nutritional supplements, and for preparing medicinal, dental, opthalmic and surgical compositions for both enteral and parenteral introduction.
Vitamin C has many known biological functions, e.g., acting as a wound healing accelerant, to prevent or treat periodontal disease, as an enzymatic co-factor,
as a "sparing" agent against vitamin E depletion, as a collagen-synthesis stimulator, etc. Vitamin C is known to counteract oxygen-containing free radicals, including both the superoxide and hydroxyl radicals. These oxidative free radicals are generated in-
vivo under a variety of normal and pathological conditions, and vitamin C is known for its ability to ameliorate conditions caused by oxygen free radicals, e.g., sunburn, cataracts, premature aging and a variety of other degenerative conditions.
The compositions of the invention comprise Vitamin C and a secondary
component which is at least one compound selected from the group consisting of 4- hydroxy-5-methyl-3(2H)-furanone, 3-hydroxy-kojic acid, threose, erythreose, and 5- hydroxymaltol. According to the presently preferred embodiment of the invention, the Vitamin C component is a mineral ascorbate, i.e., a pharmacologically acceptable salt of ascorbic acid, including salts and complexes of ascorbate anions with
pharmacologically acceptable cations of the alkali elements (sodium, potassium, etc.), alkaline-earth elements (calcium, magnesium, etc.), or transition elements (copper,
iron, zinc, chromium, etc.).
In addition to the normal utility of the Vitamin C component, these
compositions will induce improved dose-dependent, selective apoptosis of diverse human tumor cell-types, even though the concentration of the secondary component in these compositions is very low, i.e., from about .01 to about 1.0% by weight of the total composition.
The mineral ascorbates used in practicing the preferred embodiment of the invention are conveniently available as high-purity commercial products. If a single
mineral ascorbate is used, it is presently preferred to use calcium ascorbate, although it is contemplated that two or even more mineral ascorbates may be employed,
depending upon the end-use product involved.
Although calcium ascorbate is presently preferred, depending on the end-use of the finished products, other pharmacologically acceptable mineral ascorbates,
illustratively, magnesium, sodium, potassium and/or zinc ascorbates and mixtures thereof are effectively employed. The procedures for preparing the compositions of the invention are not critical
and various modifications of the procedures described below will readily occur to persons skilled in the art having regard for these disclosures, hi general the
components are merely physically admixed and then tableted with tableting excipients, encapsulated or compression molded to provide convenient dosage forms.. Alternatively, the compositions can be prepared as a stable liquid according to the processes disclosed in my issued U.S. Patent 6,197,813.
EXAMPLES
The following examples are presented to aid in understanding the invention and to illustrate the presently preferred practice thereof. As illustrations, they are not intended to limit the scope of the invention, which is defined only by the appended claims.
Example 1
The following components are mixed to provide a composition with the
components in the indicated percent by weight.
Component Wt.%
PRODUCT A calcium ascorbate 95.00
4-hydroxy-5-methyl-3(2H)-furanone 1.00
Other (ascorbic acid, dehydroascorbic acid, etc.) 4.00
PRODUCT B sodium ascorbate 96.5
3-hydroxy-kojic acid 0.2
Other 3.3 Example 2
This example illustrates the preparation of a food product, using the
compositions of the invention, e.g., the compositions of Example 1.
500 ml of dry granulated sugar is added to 125 ml of water and 125 ml of corn syrup and the mixture is stirred and brouglit to boil at 150°C. Heating is discontinued and cherry flavoring is added to taste and desired color. Product A of Example 1 is added in the quantity required to obtain the desired Vitamin C content, e.g., 30 mg Vitamin C/g of "candy" food product. The composition and the sugar-syrup base are thoroughly mixed for sufficient time to fully disperse the concentrate product. Portions of the resulting hot mixture are transferred to the cavities a candy mold and cooled to form a Vitamin C enriched hard candy product.
Having described my invention in such terms as to enable those skilled in the art to understand and practice it and, having identified the presently preferred embodiments thereof, I CLAIM:

Claims

1. A composition, comprising:
(a) a vitamin C compound; and
(b) at least one secondary compound selected from the group consisting of 4-hydroxy-5-methyl-3(2H)-furanone and 3- hydroxy-kojic acid.
2. The composition of Claim 1 wherein said vitamin C compound is a mineral ascorbate.
3. The composition of Claim 2 wherein said secondary compound is 4-hydroxy-5-methyl-3(2H)-furanone.
4. The composition of Claim 2 wherein said secondary compound is 3- hydroxy-kojic acid.
EP01958837A 2001-06-26 2001-06-26 Vitamin c compositions Ceased EP1399150A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP20140187301 EP2859894A1 (en) 2001-06-26 2001-06-26 Vitamin C compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/020431 WO2003002113A1 (en) 2001-06-26 2001-06-26 Vitamin c compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP20140187301 Division EP2859894A1 (en) 2001-06-26 2001-06-26 Vitamin C compositions

Publications (2)

Publication Number Publication Date
EP1399150A1 EP1399150A1 (en) 2004-03-24
EP1399150A4 true EP1399150A4 (en) 2006-10-11

Family

ID=21742669

Family Applications (2)

Application Number Title Priority Date Filing Date
EP01958837A Ceased EP1399150A4 (en) 2001-06-26 2001-06-26 Vitamin c compositions
EP20140187301 Withdrawn EP2859894A1 (en) 2001-06-26 2001-06-26 Vitamin C compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20140187301 Withdrawn EP2859894A1 (en) 2001-06-26 2001-06-26 Vitamin C compositions

Country Status (7)

Country Link
EP (2) EP1399150A4 (en)
JP (1) JP2004521943A (en)
CN (1) CN1313091C (en)
CA (1) CA2420548A1 (en)
MX (1) MXPA03002095A (en)
NO (1) NO327428B1 (en)
WO (1) WO2003002113A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300842A1 (en) * 1987-06-12 1989-01-25 Lvmh Recherche Pharmaceutical or cosmetic composition containing hydroquinone and kojic acid in liposomes
EP0404162A1 (en) * 1989-06-23 1990-12-27 Sansho Seiyaku Co., Ltd. Composition for treating pigmentation
US5626883A (en) * 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2780803B2 (en) * 1989-03-03 1998-07-30 ライオン株式会社 External preparation for skin
JP2809429B2 (en) * 1989-05-26 1998-10-08 湧永製薬株式会社 Anticancer agents and novel heterocyclic compounds or salts thereof useful as anticancer agents
KR920008160B1 (en) * 1990-06-01 1992-09-24 윤택구 Anticarcinogenic composition
JPH0570333A (en) * 1991-09-12 1993-03-23 Kose Corp Skin medicine for external use
ATE341938T1 (en) 1998-02-06 2006-11-15 Zila Nutraceuticals Inc STABLE LIQUID COMPOSITIONS OF CALCIUM ASCORBATE AND METHOD FOR THE PRODUCTION AND USE THEREOF
AU783283B2 (en) * 1999-08-30 2005-10-13 Ester C Company, The Methods and compositions for selective cancer chemotherapy
JP2001131572A (en) * 1999-10-29 2001-05-15 Riken Vitamin Co Ltd Antioxidant composition and oil and fat composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300842A1 (en) * 1987-06-12 1989-01-25 Lvmh Recherche Pharmaceutical or cosmetic composition containing hydroquinone and kojic acid in liposomes
EP0404162A1 (en) * 1989-06-23 1990-12-27 Sansho Seiyaku Co., Ltd. Composition for treating pigmentation
US5626883A (en) * 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO03002113A1 *

Also Published As

Publication number Publication date
CA2420548A1 (en) 2003-01-09
NO20030877D0 (en) 2003-02-25
EP2859894A1 (en) 2015-04-15
JP2004521943A (en) 2004-07-22
MXPA03002095A (en) 2004-04-02
WO2003002113A1 (en) 2003-01-09
EP1399150A1 (en) 2004-03-24
NO327428B1 (en) 2009-06-29
NO20030877L (en) 2003-04-24
CN1449284A (en) 2003-10-15
CN1313091C (en) 2007-05-02

Similar Documents

Publication Publication Date Title
KR100373393B1 (en) Tablet-type Vitamin and Calcium Complex Therapeutic Agents as Unit Herbal Medicine Agents and Their Preparation and Uses
KR100421466B1 (en) Manufacturing Method of Absorptive Zinc-Oligopeptide in The Human Body
JP2010202520A (en) Skin improver and oral composition for cosmetic and health purposes
CA2281054C (en) Combination of zinc ions and vitamin c and method of making
AU1761492A (en) Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
CN103535721A (en) Composition for improving glutathione concentration in human body and preparation method and application thereof
JP3459932B2 (en) Anti-osteoporosis composition
CA2211177C (en) Agent for acting upon bone formation disturbances containing alkaline citrates, lactates and/or malates
EP1677627B1 (en) Dietetic preparation with hyaluronate for treatment of osteoporosis
US6878744B2 (en) Vitamin C compositions
JP2002265359A (en) Kainic acid type glutamate receptor-shielding agent, ampa type glutamate receptor shielding agent, brain- protecting agent and food or drink having brain- protecting function
AU2001280448B2 (en) Vitamin C Compositions
WO2003002113A1 (en) Vitamin c compositions
AU2001280448A1 (en) Vitamin C Compositions
EP3247323B1 (en) Chlorophyll composition
JP2008150352A (en) Sleep-improving agent composition
WO2022013581A1 (en) Nutritional supplement, suitable for oral administration, comprising dihydromyricetin, choline and one or more vitamins with antioxidant activity, for use in the maintenance of normal liver function
JPH0998738A (en) Easily absorbable calcium composition
JP3250071B2 (en) Anti-osteoporosis composition
JP2000232865A (en) Production of life-vitalizing food
JP4722492B2 (en) An agent for preventing or ameliorating indefinite complaints associated with iron deficiency anemia.
KR20030022500A (en) Composition of healthfood for skin-whitening
KR20110057480A (en) Vitamin tablet comprising vitamin c mixture
MX2007002463A (en) Preparation comprising ionic iron and haem iron and variants thereof for the prophylaxis and treatment of iron deficiency.
JP2003063970A (en) Anti-osteoporosis composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030616

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ZILA NEUTRACEUTICALS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20060907

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ZILA NUTRACEUTICALS, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/34 20060101AFI20030115BHEP

Ipc: A61K 31/35 20060101ALI20060901BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE ESTER C COMPANY

17Q First examination report despatched

Effective date: 20071012

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBX Invitation to file observations in appeal sent

Free format text: ORIGINAL CODE: EPIDOSNOBA2E

APBZ Receipt of observations in appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNOBA4E

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20150612